AvroBio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
Current Price
$28.53
-1.69%Profile
Valuation (TTM)
Market Cap$543.15M
P/E-7.32
EV—
P/B2.16
Shares Out19.04M
P/Sales—
Revenue$0.00
EV/EBITDA—
AvroBio Inc (TECX) Stock Analysis
Market Cap$543.15M
Current Price$28.53
P/E Ratio-7.32
Forward P/E—
PEG Ratio0.02
EPS$-4.05
Book Value$13.20
P/B Ratio2.16
TECX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 254M
Revenue
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
TECX 52-Week Range
$14.71
$35.87
50-Day MA: $29.53200-Day MA: $22.19
Did you know?
Price sits at 65% of its 52-week range.
AvroBio Inc (TECX) Financial Summary
AvroBio Inc (TECX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $28.53 with a market capitalization of $543.15M.
Key valuation metrics include a P/E ratio of -7.32, price-to-book ratio of 2.16, and EPS of $-4.05. and return on equity of -29.5%.
TECX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $543.15M |
| P/E Ratio | -7.32 |
| EPS | $-4.05 |
| P/B Ratio | 2.16 |
| Return on Equity | -29.5% |
| Debt/Equity | 0.01 |
TECX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $0.00 | $-72.97M |
| FY20 | $0.00 | $-119.71M |
| FY21 | $0.00 | $-119.13M |
| FY22 | $0.00 | $-105.89M |
| FY23 | $0.00 | $-42.82M |
| FY24 | $0.00 | $-57.98M |
| FY25 | $0.00 | $-74.15M |
About AvroBio Inc
AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
TECX Free Cash Flow
AvroBio Inc generated $-60.22M in trailing twelve-month free cash flow, representing an FCF yield of -11.09%. This low FCF yield may reflect heavy reinvestment or growth spending.
TECX Shares Outstanding
AvroBio Inc has 0.02 billion shares outstanding at a share price of $28.53, giving it a market capitalization of $543.15M.